Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 4.88%4.34B | -1.13%8.2B | 1.09%4.14B | 19.06%8.29B | 96.61%4.1B | 114.33%6.97B | 37.25%2.08B | 27.13%3.25B | 30.27%1.52B | -11.77%2.56B |
| Operating income | 4.88%4.34B | -1.13%8.2B | 1.09%4.14B | 19.06%8.29B | 96.61%4.1B | 114.33%6.97B | 37.25%2.08B | 27.13%3.25B | 30.27%1.52B | -11.77%2.56B |
| Cost of sales | -3.07%-3.33B | 6.03%-5.99B | 0.88%-3.23B | -15.41%-6.38B | -119.53%-3.26B | -148.93%-5.53B | -48.01%-1.48B | -22.85%-2.22B | -29.33%-1B | 3.02%-1.81B |
| Operating expenses | -3.07%-3.33B | 6.03%-5.99B | 0.88%-3.23B | -15.41%-6.38B | -119.53%-3.26B | -148.93%-5.53B | -48.01%-1.48B | -22.85%-2.22B | -29.33%-1B | 3.02%-1.81B |
| Gross profit | 11.32%1.01B | 15.15%2.21B | 8.71%911.68M | 33.07%1.92B | 39.87%838.62M | 39.82%1.44B | 16.32%599.56M | 37.45%1.03B | 32.13%515.42M | -27.51%749.94M |
| Selling expenses | -4.97%-256.94M | 7.75%-496.6M | -0.64%-244.76M | -11.70%-538.29M | -6.75%-243.21M | -1.00%-481.9M | 8.01%-227.83M | -8.39%-477.14M | -25.22%-247.68M | 6.24%-440.19M |
| Administrative expenses | 0.44%-199.44M | -2.08%-375.19M | -0.80%-200.32M | -30.63%-367.54M | -20.83%-198.73M | -4.83%-281.36M | 1.79%-164.47M | -3.44%-268.39M | 0.26%-167.47M | 14.57%-259.46M |
| Research and development expenses | 8.79%-397.5M | -0.64%-864.72M | -5.18%-435.79M | -16.77%-859.2M | -79.51%-414.33M | -92.70%-735.79M | -21.07%-230.82M | -19.74%-381.83M | -34.32%-190.65M | -31.26%-318.89M |
| Revaluation surplus | 77.55%-2.27M | -44.93%-42.23M | -150.14%-10.1M | -105.52%-29.14M | 72.36%-4.04M | 33.41%-14.18M | -41.35%-14.6M | 23.62%-21.29M | -22.42%-10.33M | -424.68%-27.88M |
| -Changes in the fair value of investment property | 77.55%-2.27M | -44.93%-42.23M | -150.14%-10.1M | -105.52%-29.14M | 72.36%-4.04M | 33.41%-14.18M | -41.35%-14.6M | 23.62%-21.29M | -22.42%-10.33M | -424.68%-27.88M |
| Impairment and provision | -244.96%-30.88M | -112.97%-141.08M | -5.78%-8.95M | -57.45%-66.25M | -26.52%-8.46M | -176.66%-42.08M | 19.34%-6.69M | 66.20%-15.21M | 11.38%-8.29M | -4.00%-45M |
| -Other impairment is provision | -244.96%-30.88M | -112.97%-141.08M | -5.78%-8.95M | -57.45%-66.25M | -26.52%-8.46M | -176.66%-42.08M | 19.34%-6.69M | 66.20%-15.21M | 11.38%-8.29M | -4.00%-45M |
| Operating interest expense | ---- | ---- | ---- | ---- | -2.01%-1.32M | ---- | -440.59%-1.29M | 26.54%-1.49M | 84.50%-239K | -29.43%-2.02M |
| Special items of operating profit | -36.55%59.83M | -13.59%189.29M | 23.16%94.3M | 1.87%219.07M | 4.65%76.56M | 24.35%215.06M | -38.69%73.16M | 1.86%172.95M | 76.50%119.32M | 2.72%169.79M |
| Operating profit | 76.98%187.7M | 72.86%477.9M | 135.19%106.06M | 173.79%276.46M | 66.92%45.09M | 162.93%100.97M | 168.01%27.02M | 122.11%38.4M | 114.55%10.08M | -217.80%-173.71M |
| Financing cost | -176.84%-8.86M | -45.39%-9.26M | ---3.2M | -87.37%-6.37M | ---- | ---3.4M | ---- | ---- | ---- | ---- |
| Share of profits of associates | 5.41%3.78M | 49.04%11.44M | 17.05%3.58M | 26.91%7.68M | -59.64%3.06M | -33.03%6.05M | -30.29%7.59M | -61.96%9.03M | 4.79%10.88M | -43.59%23.74M |
| Share of profit from joint venture company | 1,160.45%3.38M | -65.81%306K | -41.10%268K | -98.01%895K | 284.21%455K | 1,695.61%45.02M | -120.10%-247K | 162.79%2.51M | -26.67%1.23M | -70.91%954K |
| Earning before tax | 74.31%186M | 72.39%480.39M | 119.51%106.71M | 87.48%278.66M | 41.50%48.61M | 197.62%148.64M | 54.81%34.35M | 133.52%49.94M | 138.78%22.19M | -177.27%-149.01M |
| Tax | -137.72%-1.75M | -27.13%-86.75M | 40.76%-737K | -186.35%-68.24M | 89.75%-1.24M | -1,026.92%-23.83M | -380.67%-12.13M | 114.69%2.57M | -158.34%-2.52M | -805.12%-17.5M |
| After-tax profit from continuing operations | 73.87%184.25M | 87.07%393.64M | 123.72%105.97M | 68.60%210.43M | 113.15%47.37M | 137.67%124.81M | 12.99%22.22M | 131.54%52.51M | 137.17%19.67M | -187.22%-166.5M |
| Earning after tax | 73.87%184.25M | 87.07%393.64M | 123.72%105.97M | 68.60%210.43M | 113.15%47.37M | 137.67%124.81M | 12.99%22.22M | 131.54%52.51M | 137.17%19.67M | -187.22%-166.5M |
| Minority profit | 311.15%1.11M | 1.60%8.94M | 114.35%269K | 43.73%8.8M | 67.62%-1.87M | 590.70%6.12M | -926.86%-5.79M | 86.82%-1.25M | 118.46%700K | 22.19%-9.46M |
| Profit attributable to shareholders | 73.26%183.14M | 90.80%384.71M | 114.66%105.7M | 69.88%201.63M | 75.80%49.24M | 120.77%118.69M | 47.68%28.01M | 134.23%53.76M | 138.62%18.97M | -177.34%-157.04M |
| Basic earnings per share | 73.22%0.1604 | 90.77%0.3369 | 114.85%0.0926 | 69.97%0.1766 | 75.92%0.0431 | 120.13%0.1039 | 46.71%0.0245 | 134.23%0.0472 | 138.75%0.0167 | -177.34%-0.1379 |
| Diluted earnings per share | 72.46%0.1597 | 90.82%0.3368 | 114.85%0.0926 | 69.87%0.1765 | 75.92%0.0431 | 121.06%0.1039 | 47.59%0.0245 | 134.08%0.047 | 138.69%0.0166 | -178.40%-0.1379 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Shin Yong Zhonghe (Hong Kong) Certified Public Accountants Limited | -- | Shin Yong Zhonghe (Hong Kong) Certified Public Accountants Limited | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.